The Bloomberg View Senior Executive Editor David Shipley presents an editorial arguing that Americans will not benefit from a new law allowing them to sidestep the Food and Drug Administration and experiment with medicines of questionable safety that may or may not work. This editorial aired on Bloomberg Radio.